Rate advancement measurement for lung cancer and pleural mesothelioma in asbestos-exposed workers.
Humans
Asbestos
/ toxicity
Cohort Studies
Italy
/ epidemiology
Lung Neoplasms
/ epidemiology
Mesothelioma
/ epidemiology
Mortality
/ trends
Occupational Diseases
/ epidemiology
Occupational Exposure
/ adverse effects
Pleural Neoplasms
/ epidemiology
Risk Assessment
Male
Female
Construction Industry
Adult
Middle Aged
Aged
asbestos induced lung disease
lung cancer
mesothelioma
Journal
Thorax
ISSN: 1468-3296
Titre abrégé: Thorax
Pays: England
ID NLM: 0417353
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
26
06
2021
accepted:
13
10
2022
medline:
17
7
2023
pubmed:
11
11
2022
entrez:
10
11
2022
Statut:
ppublish
Résumé
Exposure to asbestos increases the risk of lung cancer and mesothelioma. Few studies quantified the premature occurrence of these diseases in asbestos-exposed workers. Focus on premature disease onset (rate advancement or acceleration) can be useful in risk communication and for the evaluation of exposure impact. We estimated rate advancement for total mortality, lung cancer and pleural mesothelioma deaths, by classes of cumulative asbestos exposure in a pooled cohort of asbestos cement (AC) workers in Italy. The cohort study included 12 578 workers from 21 cohorts, with 6626 deaths in total, 858 deaths from lung cancer and 394 from pleural malignant neoplasm (MN). Rate advancement was estimated by fitting a competitive mortality Weibull model to the hazard of death over time since first exposure (TSFE). Acceleration time (AT) was estimated at different TSFE values. The highest level of cumulative exposure compared with the lowest, for pleural MN AT was 16.9 (95% CI 14.9 to 19.2) and 33.8 (95% CI 29.8 to 38.4) years at TSFE of 20 and 40 years, respectively. For lung cancer, it was 13.3 (95% CI 12.0 to 14.7) and 26.6 (95% CI 23.9 to 29.4) years, respectively. As for total mortality, AT was 3.35 (95% CI 2.98 to 3.71) years at 20 years TSFE, and 6.70 (95% CI 5.95 to 7.41) at 40 years TSFE. The current study observed marked rate advancement after asbestos exposure for lung cancer and pleural mesothelioma, as well as for total mortality.
Identifiants
pubmed: 36357176
pii: thorax-2021-217862
doi: 10.1136/thorax-2021-217862
doi:
Substances chimiques
Asbestos
1332-21-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
808-815Investigateurs
Lisa Bauleo
(L)
Antonio Baldassarre
(A)
Carol Brentisci
(C)
Barbara Cortini
(B)
Stefania Curti
(S)
Manuela Gangemi
(M)
Giuseppe Gorini
(G)
Patrizia Legittimo
(P)
Francesco Marinelli
(F)
Pasqualina Marinilli
(P)
Stefano Mattioli
(S)
Marina Musti
(M)
Chiara Panato
(C)
Venere LedaMara Pavone
(VL)
Alessandra Ranucci
(A)
Elisa Romeo
(E)
Corrado Scarnato
(C)
Cinzia Storchi
(C)
Antonella Stura
(A)
Simona Verdi
(S)
Informations de copyright
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: The authors declare that they have no competing interests. The following authors or working group components reported that they served as expert witness in court trials on asbestos related diseases: AA, AB, CM, DM, EM, EO, FB-A, LBi, LMa, LMi, MM, SMe, SS, VP.